Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term CANCER. Found 56 abstracts

no pagination
Gao WZ, Ma GX, Tan Y, Fang C, Weaver J, Jin M, Lai P, Godwin AK. Culturally Appropriate Education Intervention on Biospecimen Research Participation among Chinese Americans. Cancer Epidemiology Biomarkers & Prevention. 2014 Mar;23(3):383-91.   PMCID: PMC 3955025
Garcia JA, Hudes GR, Choueiri TK, Stadler WM, Wood LS, Gurtler J, Bhatia S, Joshi A, Hozak RR, Xu YH, Schwartz JD, Thompson JA. A Phase 2, Single-Arm Study of Ramucirumab in Patients With Metastatic Renal Cell Carcinoma With Disease Progression on or Intolerance to Tyrosine Kinase Inhibitor Therapy. Cancer. 2014 Jun;120(11):1647-55.   PMCID: No NIH funding
Pond GR, Agarwal N, Bellmunt J, Choueiri TK, Qu A, Fougeray R, Vaughn D, James ND, Salhi Y, Albers P, Niegisch G, Galsky MD, Wong YN, Ko YJ, Stadler WM, O'Donnell PH, Sridhar SS, Vogelzang NJ, Necchi A, Di Lorenzo G, Sternberg CN, Mehta A, Sonpavde G. A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma. BJU international. 2014 May;113(5B):E137-E143.
Prebet T, Sun ZX, Figueroa ME, Ketterling R, Melnick A, Greenberg PL, Herman J, Juckett M, Smith MR, Malick L, Paietta E, Czader M, Litzow M, Gabrilove J, Erba HP, Gore SD, Tallman MS. Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905. Journal of Clinical Oncology. 2014 Apr;32(12):1242-8.   PMCID: PMC3986386
von Mehren M, Randall RL, Benjamin RS, Boles S, Bui MM, Casper ES, Conrad EU, DeLaney TF, Ganjoo KN, George S, Gonzalez RJ, Heslin MJ, Kane JM, Mayerson J, McGarry SV, Meyer C, O'Donnell RJ, Pappo AS, Paz IB, Pfeifer JD, Riedel RF, Schuetze S, Schupak KD, Schwartz HS, Van Tine BA, Wayne JD, Bergman MA, Sundar H. Soft Tissue Sarcoma, Version 2.2014 Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network. 2014 Apr;12(4):473-83.   PMCID: No NIH funds
Narvekar M, Xue HY, Wong HL. A novel hybrid delivery system: Polymer-oil nanostructured carrier for controlled delivery of highly lipophilic drug all-trans-retinoic acid (ATRA). Int J Pharm. 2012 Oct;436(1-2):721-31.
Daniel LC, Heckman CJ, Kloss JD, Manne SL. Comparing alternative methods of measuring skin color and damage. Cancer Causes & Control. 2009 Apr;20(3):313-21.   PMCID: PMC2702995
Kadariya Y, Yin B, Tang BQ, Shinton SA, Quinlivan EP, Hua X, Klein-Szanto A, Al-Saleem TI, Bassing CH, Hardy RR, Kruger WD. Mice Heterozygous for Germ-line Mutations in Methylthioadenosine Phosphorylase (MTAP) Die Prematurely of T-Cell Lymphoma. Cancer Research. 2009 Jul;69(14):5961-9.   PMCID: PMC2757012
Rothman J, Egleston B, Wong YN, Iffrig K, Lebovitch S, Uzzo RG. Histopathological Characteristics of Localized Renal Cell Carcinoma Correlate With Tumor Size: A SEER Analysis. Journal of Urology. 2009 Jan;181(1):29-33.   PMCID: PMC2782573
Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, Chidel MA, Pugh TJ, Franklin W, Kane M, Gaspar LE, Schefter TE. Multi-Institutional Phase I/II Trial of Stereotactic Body Radiation Therapy for Liver Metastases. Journal of Clinical Oncology. 2009 Apr;27(10):1572-8.   PMCID: not NIH funded
Scoll BJ, Wong YN, Egleston BL, Kunkle DA, Saad IR, Uzzo RG. Age, Tumor Size and Relative Survival of Patients With Localized Renal Cell Carcinoma: A Surveillance, Epidemiology and End Results Analysis. Journal of Urology. 2009 Feb;181(2):506-11.   PMCID: PMC 2703466
Zagurovskaya M, Shareef MM, Das A, Reeves A, Gupta S, Sudol M, Bedford MT, Prichard J, Mohiuddin M, Ahmed MM. EGR-1 forms a complex with YAP-1 and upregulates Bax expression in irradiated prostate carcinoma cells. Oncogene. 2009 Feb;28(8):1121-31.
Zorn KK, Tian CQ, McGuire WP, Hoskins WJ, Markman M, Muggia FM, Rose PG, Ozols RF, Spriggs D, Armstrong DK. The Prognostic Value of Pretreatment CA 125 in Patients With Advanced Ovarian Carcinoma A Gynecologic Oncology Group Study. Cancer. 2009 Mar;115(5):1028-35.   PMCID: PMC 2664510
Ahmed MM, Sheldon D, Fruitwala MA, Venkatasubbarao K, Lee FY, Gupta S, Wood C, Mohiuddin M, Strodel WE. Downregulation of PAR-4, a pro-apoptotic gene, in pancreatic tumors harboring K-ras mutation. International journal of cancer. 2008 Jan;122(1):63-70.
Blay JY, von Mehren M, Samuels BL, Fanucchi MP, Ray-Coquard I, Buckley B, Gilles L, Lebedinsk C, Elsayed YA, Le Cesne A. Phase I Combination Study of Trabectedin and Doxorubicin in Patients with Soft-Tissue Sarcoma. Clinical Cancer Research. 2008 Oct;14(20):6656-62.
Cardenas-Turanzas M, Follen M, Nogueras-Gonzalez GM, Benedet JL, Beck JR, Cantor SB. The Accuracy of the Papanicolaou Smear in the Screening and Diagnostic Settings. Journal of Lower Genital Tract Disease. 2008 Oct;12(4):269-75.
Choi YS, Hoory T, Monie A, Wu A, Connolly D, Hung CF. alpha-Galactosylceramide enhances the protective and therapeutic effects of tumor cell based vaccines for ovarian tumors. Vaccine. 2008 Oct;26(46):5855-63.
Eytan E, Braunstein L, Ganoth D, Teichner A, Hittle JC, Yen TJ, Hershko A. Two different mitotic checkpoint inhibitors of the anaphase-promoting complex/cyclosome antagonize the action of the activator Cdc20. Proceedings of the National Academy of Sciences of the United States of America. 2008 Jul;105(27):9181-5.
Glanz K, Yaroch AL, Dancel M, Saraiya M, Crane LA, Buller DB, Manne S, O'Riordan DL, Heckman CJ, Hay J, Robinson JK. Measures of sun exposure and sun protection practices for behavioral and epidemiologic research. Archives of Dermatology. 2008 Feb;144(2):217-22.
Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A, Benson AB, Macdonald JS, Kudrimoti MR, Fromm ML, Haddock MG, Schaefer P, Willett CG, Rich TA. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma - A randomized controlled trial. JAMA-Journal of the American Medical Association. 2008 Mar;299(9):1019-26.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term CANCER

CANCER Oncology SURVIVAL TUMORS CARCINOMA UNITED-STATES SUNBURN P53 ADENOCARCINOMA RADIATION-THERAPY renal cell carcinoma PHASE-III ADULTS PACLITAXEL CA-125 OLD III TRIAL FREQUENT SOMATIC MUTATIONS sensitivity and specificity alpha-Galactosylceramide COMBINATION IMMUNITY EPITHELIAL-CELLS RESECTION VINFLUNINE NANOCAPSULES Spectrophotometry MOSEC SOLID LIPID NANOPARTICLES SPINDLE CHECKPOINT CONTINUOUS INTRAVENOUS-INFUSION YES-ASSOCIATED PROTEIN MESOTHELIN-EXPRESSING TUMORS KRN7000 phase 2 SINGLE GROUP ACTIVATION CODELETION RESISTANCE PLGA NANOPARTICLES Urology & Nephrology NKT progression-free survival at CELL-LINE GENE DELETION APC PREVENTION RETROPERITONEAL SARCOMA ANTIGEN ramucirumab ORNITHINE-DECARBOXYLASE ANTIGENS BURST RELEASE OF-THE-ART MONOCLONAL-ANTIBODY CERVICAL CYTOLOGY GROUP-B CARBOPLATIN HOMOZYGOUS DELETIONS GERMLINE MUTATIONS SURGERY HISTONE DEACETYLASE INHIBITION YAP-1 EGR-1-Bax-prostate cancer-radiation HEALTH-RISK BEHAVIORS advanced urothelial cancer PROGRAM CONVENTIONAL CARE REGIMENS IFN-GAMMA TRANSCRIPTION INDUCTION TRACT INDEPENDENT PROGNOSTIC-FACTOR CHEMOTHERAPY GLYCOLIPID LUNG DOMAIN monoclonal SEER program FAMILIAL ADENOMATOUS POLYPOSIS retinoic acid SELECTION PLGA LINE P53 metastatic CA 125 tumor marker MUTATIONS COOPERATIVE-ONCOLOGY-GROUP APPEARANCE-BASED INTERVENTIONS GROWTH 6 months PHOSPHORYLATION second-line therapy IONIZING-RADIATION MANAGEMENT VALPROIC ACID IMMUNOTHERAPY NEOPLASMS SUNITINIB kidney neoplasms ELECTRON-BEAM RADIOTHERAPY CURATIVE RESECTION progression-free survival INTRAPERITONEAL CISPLATIN PHASE-III TRIAL SYSTEM H-RAS pathology Controlled drug delivery mortality Group TIME ULTRAVIOLET-RADIATION EXPOSURE C SORAFENIB Tumor cell-based vaccines cervix neoplasms ECTEINASCIDIN-743 ET-743 response rate Environmental & Occupational Health Public CYCLOSOME epithelial ovarian cancer EUROPEAN-ORGANIZATION screening STAGE REGIMEN MODEL CDKN2 CARNEY-STRATAKIS COMMUNITY COMPOUND YOUNG-ADULTS SBRT TRANSITIONAL-CELL CARCINOMA GENE ONCOGENIC RAS cervical intraepithelial neoplasia BIOAVAILABILITY Ovarian pancreatic cancer PAR-4-K-ras mutation-survival PHASE-II TRIAL IN-VITRO EXPERIENCE UBIQUITINATION SOLID MALIGNANCIES PROGRAMMED CELL-DEATH ANTITUMOR-ACTIVITY PROTEIN PAR-4 REFLECTANCE TRENDS Nanomedicine
Last updated on Friday, January 03, 2020